Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nagoya Firm Discovers A System To Deliver Drugs Into Brain

This article was originally published in PharmAsia News

Executive Summary

Nagoya-based Tissue Targeting Japan Inc. has developed the T2J peptide, a synthetic molecule that is able to permeate the blood-brain barrier and deliver drugs and materials directly inside human brains. Until now, the blood-brain barrier has blocked viruses and toxins as well as drugs from entering the brain. The T2J research team discovered that the microglial cell, a certain kind of glial cell, which accounts for 90 percent of brain cells, has the ability to permeate the brain blood barrier. Modeled after the microglial cell's movement pattern inside the brain, the T2J peptide can deliver chemicals directly to the brain. Tissue Targeting Japan will strengthen joint research with pharmaceutical companies and expects to launch a new drug using the peptide in 2015. (Click here for more-Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel